Canopy Growth Corporation saw its stock price surge 24% after President Trump announced his administration would consider rescheduling cannabis. The Canadian cannabis producer led gains across the sector as investors responded to the potential policy change.
Canopy Growth Corporation, CGC
The rally affected multiple Canadian cannabis companies trading on both the Toronto Stock Exchange and Nasdaq. Canopy Growth trades under the ticker symbols WEED in Canada and CGC in the United States.
Trump expected to direct his administration to move to reclassify marijuana as a less dangerous drug, according to people familiar with the matter https://t.co/ipQHLXjopj
— Bloomberg (@business) December 12, 2025
Canopy Growth currently trades at $1.57 CAD on the Toronto Stock Exchange with a market cap of $537.25 million. The stock has experienced extreme volatility over the past year, down 68.28% from its previous highs.
The company’s 52-week trading range spans from $1.085 to $4.950 per share. Daily trading volume reached 846,354 shares, below its average volume of 1,508,194 shares.
Canopy Growth produces and sells cannabis, hemp, and related products in Canada, Germany, and Australia through four business segments. The company offers dried flower, pre-rolled joints, extracts, edibles, vapes, and oils under brands including Tweed and 7ACRES.
The Smiths Falls, Ontario-based company employs 960 people and was founded in 2009. It operates in the drug manufacturers specialty and generic sector within the healthcare industry.
Canopy Growth reported second quarter fiscal 2026 results four weeks ago, showing improved financial performance. The company posted revenue of $66.68 million CAD for the quarter ended September 2025.
The quarterly results showed a loss per share of $0.01 CAD, beating analyst expectations by $0.17 CAD. However, revenue missed estimates by $5.14 million CAD.
For the full year 2024, Canopy Growth recorded revenue of $269 million, representing a 9.47% decrease from the previous year’s $297.15 million. Annual losses totaled $598.12 million, which was 9% less than 2023 losses.
The company reported trailing twelve-month revenue of $278.61 million with net losses of $385.85 million. Earnings per share for the trailing twelve months stood at negative $2.12.
Canopy Growth has outlined plans to improve margins and cash flow through Canadian cannabis momentum. The company recently launched new products including Claybourne Gassers Liquid Diamonds vapes in Canada and expanded its Spectrum Therapeutics portfolio in Australia with new softgels.
Investors have been closely watching Canopy Growth as the stock appears frequently in market analyses. The company’s next earnings report is scheduled for February 6, 2026.
Experts caution that cannabis stocks remain volatile despite the recent rally. The potential for U.S. cannabis rescheduling under the Trump administration has created speculation across the sector, but policy changes remain uncertain.
Canopy Growth’s stock closed at $1.59 CAD on December 11, 2025, down $0.020 or 1.26% from the previous trading session.
The post Canopy Growth Soars 24% as Trump Signals Cannabis Policy Shift appeared first on CoinCentral.
